Analysis shows 'herbal' ED products contaminated with PDE-5 inhibitors
Some "herbal" products marketed as having efficacy similarto PDE-5 inhibitors without the side effects and the need for medical monitoringactually contain pharmacologic concentrations of PDE-5 inhibitors, accordingto the results of a Canadian study presented here. Separately, Britishresearchers confirmed what many urologists already know-that informationabout herbal ED therapies sold on the Internet is unreliable and misleading.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.